- Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective AnalysisWu, Shaojie; Tu, Sanfang; Zhou, Zhenjun; Sun, Xinlin; Wu, Anqin; Wang, Lei; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trialHuang, Y.; Wu, T.; Hu, Y.; Li, Y.; Ma, J.; Guo, Y.; Zhou, H.; Yang, R.; Gong, Y.; Zhang, Q. Y.; Lin, L. E.; Zhou, R.; Liu, Y.; Pan, Z.; Xue, J.; Wang, D.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
- Treatment of Acute Lymphoblastic Leukemia with PDT Regimen Improves the Prognosis of Newly Diagnosed Central Nervous System LeukemiaLiang, Haimei; Liu, Qifa; Zhou, Hongsheng65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study
8阅读
